- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Role of PCSK9 Inhibitors for Patients with Hyperlipidemia
Zachary T. Bloomgarden, MD, MACE: We know that some individuals will receive a potent statin, or as much of a statin as they can tolerate (because some people develop really burdensome musculoskeletal complaints with statins). Yet, we’ll have evidence of atherosclerotic cardiovascular disease and have LDL (low-density lipoprotein) cholesterol levels [that] are above goal.
For such individuals, we now have a few choices [for treatment]. We can use the bile acid binding resins. We can use ezetimibe. We now can use the PCSK9 (proprotein convertase subtilisin kexin 9) inhibitors, which are tremendously potent agents for lowering LDL cholesterol and seem to be rather well tolerated.
I think this, essentially, represents a huge advance in the way that the dyslipidemia will be treated going forward. There’s the cost issue. There’s all these other things which are so important. So, we have to see how it all plays out, but the fact that we have so many choices is only going to help us to do a better job.
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
